This HTML5 document contains 209 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n13http://dx.doi.org/10.1186/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n12https://scigraph.springernature.com/pub.10.1186/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34433040
rdf:type
wikibase:Item
schema:description
artikulong pang-agham artigo científico (publicado na 2012) επιστημονικό άρθρο scienca artikolo 2012年论文 2012年の論文 bài báo khoa học wetenschappelijk artikel vitenskapelig artikkel 2012 թվականի հոտեմբերին հրատարակված գիտական հոդված научная статья 2012年论文 2012년 논문 naučni članak vedecký článok мақолаи илмӣ 2012年論文 vitskapeleg artikkel мақолаи илмӣ article scientific наукова стаття, опублікована в жовтні 2012 مقالة علمية научни чланак научни чланак 2012年论文 ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2012 nî lūn-bûn bilimsel makale 2012年論文 tieteellinen artikkeli مقالهٔ علمی teaduslik artikkel wissenschaftlicher Artikel 2012年论文 מאמר מדעי artikull shkencor 2012年論文 scientific article บทความทางวิทยาศาสตร์ mokslinis straipsnis article científic artigo científico (publicado na 2012) vetenskaplig artikel 2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած artículu científicu espublizáu en 2012 2012年論文 artigo científico article scientifique (publié 2012) tudományos cikk artículo científico publicado en 2012 научна статия articol științific vědecký článek 2012年論文 სამეცნიერო სტატია articolo scientifico artykuł naukowy 2012年论文 videnskabelig artikel (udgivet 2012) سائنسی مضمون 2012年论文
p:P577
wds:Q34433040-1240BA01-939E-48BC-A52B-ACF98E165B75
wdt:P577
2012-10-03T00:00:00Z
p:P407
wds:Q34433040-DD91D33E-2C37-45C8-98F4-4429863BA011
wdt:P407
wd:Q1860
p:P2888
wds:Q34433040-7A3F89FF-D54F-4411-B026-1553445FF065
wdt:P2888
n12:1471-2407-12-449
p:P2860
wds:Q34433040-0537E0FB-C5EE-4117-BF54-81AFFE25F94C wds:Q34433040-11B89197-434E-4272-A670-DCF3E25A618A wds:Q34433040-14F907E9-0122-499D-95AD-2BF240F20596 wds:Q34433040-15901040-10C8-4D7C-815A-687AED30174B wds:Q34433040-17CC07DB-D814-4328-B5AF-8C94F59A9C4B wds:Q34433040-1B5173B7-9812-44C7-AD51-59F2E130D5CA wds:Q34433040-1B9F37E0-E86E-439A-8B42-F6973C18A0A9 wds:Q34433040-1C743C07-A93E-4A68-A392-708E836A0916 wds:Q34433040-1F2843C7-B636-4EA5-8A36-C6C0E822F5F9 wds:Q34433040-24807D60-3933-4381-8634-B140FCE397A8 wds:Q34433040-27407DA7-73BF-474F-BC5F-62AD1857AB89 wds:Q34433040-286333EA-DBCD-4070-B25A-029BACE001AF wds:Q34433040-36E29B33-2A22-445C-AAF4-41049563CDC7 wds:Q34433040-39157C17-A29F-4DCB-AADC-32910511D1E0 wds:Q34433040-3F2C6784-E364-40B4-8C86-70451222CCBF wds:Q34433040-436C9A5C-C333-49A5-8947-72BEC71B3662 wds:Q34433040-4AA7E798-A580-4CA5-816D-7D07D2474B0B wds:Q34433040-4E0E2AE1-85E4-4B7C-8741-B9ECEBE52255 wds:Q34433040-51B710EE-4B33-41D6-9E53-DB3D3E3B69B0 wds:Q34433040-54A7C5AE-D595-4873-A101-0A38EB059492 wds:Q34433040-58EFFB67-4534-4906-B40E-A783F412F616 wds:Q34433040-5B3A081D-CC20-4D9D-B236-41A2E567CD3A wds:Q34433040-5C2CF069-504F-400B-B4BF-0E060F0DDF04 wds:Q34433040-603D67A2-AC19-4253-A337-A3AEF1EDC123 wds:Q34433040-62560D80-FD0D-4A87-9CEB-10A064F2E836 wds:Q34433040-831ABA7B-CF51-4E7F-A0F4-3A18FF93B816 wds:Q34433040-8838FC94-57E1-4FE4-A07F-71E8BF2609C8 wds:Q34433040-89D6970F-9433-4EAA-9833-C66BFA6B143F wds:Q34433040-96F91C91-C96D-4C4B-9A81-1988B7CFF580 wds:Q34433040-9AB9CC5C-5AA2-442E-A81E-5D5C6BDFE340 wds:Q34433040-9D50BC40-65F1-496E-A82D-49DC71732705 wds:Q34433040-A7EB79EA-8597-4BCF-B5C1-161962711FAA wds:Q34433040-AAB62B8D-3E92-41CC-821A-6F09C15EC5DA wds:Q34433040-B0BEEA10-C0B9-47AF-8999-F8782C334D9B wds:Q34433040-B2863586-B632-4E14-9DC1-9B1D3D6CE515 wds:Q34433040-B7B8C0B3-B6B3-44CF-B3DA-0E21438E343E wds:Q34433040-BE81BB65-F6DD-484E-A5DC-191DE55A1213 wds:Q34433040-C80F8BD5-3C06-4DAF-8B96-2762BC35CDE6 wds:Q34433040-CB27ED34-9C2E-49FB-9FA4-FB3D99600AA8 wds:Q34433040-D70CFBA7-3FFF-4E21-92C6-AF8987F53769 wds:Q34433040-DC147DC6-0DCB-4C03-8229-8F75C22D83F6 wds:Q34433040-F065E972-60F7-4557-9E0B-B047CED1C8A2 wds:Q34433040-FB654DB9-6B7D-4C25-ACB4-DEC4927A06AD wds:Q34433040-FE90D153-0F9C-424B-B954-E8871A5CD8EC
wdt:P2860
wd:Q40226887 wd:Q77372791 wd:Q24681191 wd:Q80025942 wd:Q37372615 wd:Q53518274 wd:Q35575875 wd:Q36611170 wd:Q39710748 wd:Q41139696 wd:Q36073411 wd:Q33922852 wd:Q35234955 wd:Q29619719 wd:Q31963937 wd:Q34461490 wd:Q81358289 wd:Q27860904 wd:Q35613883 wd:Q33997854 wd:Q43236873 wd:Q50782266 wd:Q35163538 wd:Q79548601 wd:Q40632066 wd:Q81897400 wd:Q31463890 wd:Q78693676 wd:Q40384762 wd:Q46972241 wd:Q29547376 wd:Q84738989 wd:Q48136888 wd:Q44164588 wd:Q36015542 wd:Q46489542 wd:Q40297687 wd:Q39768023 wd:Q40660384 wd:Q44346771 wd:Q50920561 wd:Q53281098 wd:Q37047747 wd:Q43578049
p:P2093
wds:Q34433040-BC6C7F8B-EBE5-4337-BC70-51535D7DD423 wds:Q34433040-748D2582-209E-43F7-A250-93D99845F2A3 wds:Q34433040-5B3A8300-E4B3-455A-A96B-CE798D86AA35 wds:Q34433040-7EF01E2B-FF15-4535-B7A6-6B202B5AA896 wds:Q34433040-1AE91C18-4D17-4A2A-AB62-AB028891F6F5 wds:Q34433040-2668DF9A-2A38-41CE-9C7B-6A1997550889 wds:Q34433040-1F174050-E5F1-46CF-A2F0-5EB98E2DA5C2
wdt:P2093
Dennie V Jones Laurie L Carr Sang-Joon Lee Sarah G Wallace Julie E Bauman Lisa A Cerilli Renato G Martins
rdfs:label
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
skos:prefLabel
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
schema:name
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
p:P50
wds:Q34433040-4C85C14E-68AA-4F96-8064-8C787F096EFB wds:Q34433040-36F5DA46-9A47-4966-BA6B-EC8DE5A14E06
wdt:P50
wd:Q91360997 wd:Q57065724
p:P1476
wds:Q34433040-25E25CF1-061E-46FA-81B4-7A224F68B353
wdt:P1476
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
p:P304
wds:Q34433040-468AE49F-727C-4922-BD82-3B391952D754
wdt:P304
449
p:P31
wds:Q34433040-44050D18-29B1-4269-B7B0-26EDDE67A059
wdt:P31
wd:Q13442814
p:P921
wds:Q34433040-3A575AA1-129E-4E96-964E-F06F53EAEC62 wds:Q34433040-6F4DCDC2-78BB-474E-8099-E2087B3A0E63
wdt:P921
wd:Q177094 wd:Q423762
p:P698
wds:Q34433040-38F4F044-0EAD-44E7-82BB-71888B5827B7
wdtn:P698
n9:23033932
wdt:P698
23033932
p:P1433
wds:Q34433040-C2858D05-15BF-4CA0-8B14-4EEB4F4BD88B
wdt:P1433
wd:Q326300
p:P478
wds:Q34433040-F8B8F39B-FE95-48EA-A313-44BA9FBF86FB
wdt:P478
12
p:P356
wds:Q34433040-CB631FB0-8C2F-482C-A2E0-02543D706D51
wdtn:P356
n13:1471-2407-12-449
wdt:P356
10.1186/1471-2407-12-449
p:P5875
wds:Q34433040-9B94CD69-6DC8-46A0-8BE3-67B2CF689E1B
wdt:P5875
232007027
p:P6179
wds:Q34433040-41C3AFBB-142F-4018-B8A8-7CDCD9225D2B
wdt:P6179
1017854300
p:P932
wds:Q34433040-FDCE13CD-F659-4ADE-A8A1-2B8A52DFB462
wdt:P932
3517479